Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments”
🏛 Food and Drug Administration (FDA)FDA-2026-N-3273
Documents
1
Total comments
0
all analyzed
Comment status
Open
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
- Notice· Apr 15, 2026Closed on Jul 24, 2026